Physiological and tumor-associated angiogenesis: Key factors and therapy targeting VEGF/VEGFR pathway.
Level 5 - mechanism / opinion, no new human data
Narrative review of biological mechanisms and clinical therapies without systematic review methodology
PubMed 39442237 · doi:10.1016/j.biopha.2024.117585
What was done
This narrative review summarizes the key factors and mechanisms distinguishing physiological from tumor-associated angiogenesis. It details molecular targets within tumor vasculature, focusing primarily on the VEGF/VEGFR pathway, and examines the clinical protocols, advantages, and limitations of therapies directed at this pathway.
What was found
The abstract reports no quantitative data or numerical outcomes. It highlights tumor angiogenesis as a key driver of growth and metastasis, identifies VEGF/VEGFR signaling as a primary therapeutic target, and outlines the general advantages and limitations of existing clinical protocols targeting this pathway.
Why it matters
It synthesizes the mechanistic rationale and clinical status of VEGF/VEGFR-targeted antiangiogenic strategies in cancer therapy.
Limits
The publication is a narrative review without original experimental data, systematic methodology, or quantitative pooling. The abstract lacks specifics on evaluated clinical regimens, comparative outcomes, and study selection criteria.
Cited by
- supports Cancer utilizes vascular endothelial growth factor (VEGF) to establish blood supply and facilitate metastasis from primary tumors.